`
`Drug
`
`Sanctura XR
`
`Sanctura
`
`Vesicare
`
`Oxytrol
`
`2008
`
`[A]
`
`2009
`
`[B]
`
`2010
`
`[B]
`
`2011
`
`[C]
`
`2012
`
`[C]
`
`2013
`
`[D]
`
`2014
`
`[D]
`
`9.7%
`
`1.0%
`
`31.5%
`
`5.2%
`
`4.9%
`
`0.8%
`
`34.3%
`
`1.6%
`
`6.5%
`
`1.4%
`
`37.1%
`
`0.1%
`
`2.4%
`
`1.1%
`
`44.6%
`
`0.1%
`
`8.1%
`
`0.8%
`
`0.8%
`
`39.3%
`
`0.1%
`
`6.4%
`
`0.3%
`
`0.5%
`
`26.7%
`
`0.1%
`
`2.2%
`
`0.4%
`
`0.7%
`
`21.9%
`
`0.1%
`
`0.2%
`
`2015
`(Jan - Oct)
`[D]
`
`0.2%
`
`0.5%
`
`26.8%
`
`0.2%
`
`0.1%
`
`Gelnique
`
`Enablex
`
`Detrol LA
`
`Detrol
`
`Toviaz
`
`0.0%
`
`18.6%
`
`32.5%
`
`1.5%
`
`0.0%
`
`5.9%
`
`20.8%
`
`11.9%
`
`0.7%
`
`19.0%
`
`8.9%
`
`14.9%
`
`1.1%
`
`0.1%
`
`29.9%
`
`13.4%
`
`1.3%
`
`0.2%
`
`28.6%
`
`9.0%
`
`2.7%
`
`0.2%
`
`35.3%
`
`6.7%
`
`1.7%
`
`0.2%
`
`20.0%
`
`5.9%
`
`1.1%
`
`0.4%
`
`21.8%
`
`2.0%
`
`0.7%
`
`0.5%
`
`18.4%
`
`Total details
`
`
`
`1,109
`
`
`
`1,043
`
`
`
`1,154
`
`
`
`1,073
`
`
`
`1,075
`
`
`
`919
`
`
`
`758
`
`
`
`634
`
`Notes and sources:
`Total details are in thousands.
`[A] UBS, "U.S. Pharmaceuticals," 11/26/2010, at 73, Table 70.
`[B] UBS, "U.S. Pharmaceuticals," 8/24/2011, at 89, Table 86.
`[C] UBS, "U.S. Pharmaceuticals," 11/15/2013, at 100, Table 95.
`[D] UBS, "U.S. Pharmaceuticals," 1/4/2016, at 93, Figure 85.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1048 - Page 1
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1048 - Page 1